Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Taichi Nagahisa, Yoshifumi Saisho
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1733-1752
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer
J. A. M. J. L. Janssen
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 7797-7797
Open Access | Times Cited: 186
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease
Amgad Zaky, Sarah Glastras, May Wong, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9641-9641
Open Access | Times Cited: 127
The cardio-renal-metabolic connection: a review of the evidence
Marella Marassi, Gian Paolo Fadini
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 88
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases (2020) Vol. 8, Iss. 2, pp. 14-14
Open Access | Times Cited: 100
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 94
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Sirtuins and Renal Oxidative Stress
Yoshio Ogura, Munehiro Kitada, Daisuke Koya
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1198-1198
Open Access | Times Cited: 41
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 8, pp. 322-322
Open Access | Times Cited: 20
Dapagliflozin: A Review in Type 1 Diabetes
Julia Paik, Hannah A. Blair
Drugs (2019) Vol. 79, Iss. 17, pp. 1877-1884
Open Access | Times Cited: 47
Metformin and cardiorenal outcomes in diabetes: A reappraisal
John R. Petrie, Peter Rossing, Ian W Campbell
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 6, pp. 904-915
Open Access | Times Cited: 44
Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective
Soumik Das, Gnanasambandan Ramanathan
Life Sciences (2023) Vol. 316, pp. 121414-121414
Closed Access | Times Cited: 14
Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
Vaia Lambadiari, J Thymis, Demetrios Kouretas, et al.
Antioxidants (2021) Vol. 10, Iss. 9, pp. 1379-1379
Open Access | Times Cited: 29
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as a Dual Therapeutic Target for Cardiovascular and Renal Health: A Narrative Review
Sulthan Al Rashid, Inamul Hasan Madar, Iffath Misbah, et al.
Ibnosina Journal of Medicine and Biomedical Sciences (2025)
Open Access
Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Anu Grover, Komal Sharma, Suresh Gautam, et al.
Current Diabetes Reviews (2020) Vol. 17, Iss. 4, pp. 397-420
Closed Access | Times Cited: 30
Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective
Khurshid Ahmad, Sibhghatulla Shaikh, Jeong Ho Lim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115642-115642
Open Access | Times Cited: 10
Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes
Luxcia Kugathasan, Vikas S. Sridhar, Kalie L. Tommerdahl, et al.
Metabolism (2024) Vol. 153, pp. 155785-155785
Open Access | Times Cited: 3
Association of hypoglycemic agents with the risk of platinum-based chemotherapy-induced peripheral neuropathy in patients with type 2 diabetes mellitus
Takeshi Horii, Kenji Onda, Airi Yutasaka, et al.
(2025)
Closed Access
Incretin therapy for diabetes mellitus type 2
Jens J. Holst
Current Opinion in Endocrinology Diabetes and Obesity (2019) Vol. 27, Iss. 1, pp. 2-10
Closed Access | Times Cited: 27
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
Natasha Srinivas, Mubashira K Sarnaik, Srimy Modi, et al.
Cureus (2021)
Open Access | Times Cited: 18
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
Rabia Khalid Alduraibi, Yazeed Mohammed Alrebdi, Yosef Fahad Altowayan
Medicine (2023) Vol. 102, Iss. 23, pp. e34027-e34027
Open Access | Times Cited: 7
Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS
Bassam M. Ayoub, Haidy E. Michel, Shereen Mowaka, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 889-889
Open Access | Times Cited: 16
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1754-1764
Closed Access | Times Cited: 16
Adipocyte function and the development of cardiometabolic disease
Maude Giroud, Henrika Jodeleit, Kacey J. Prentice, et al.
The Journal of Physiology (2021) Vol. 600, Iss. 5, pp. 1189-1208
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top